Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

被引:3270
作者
Bikbov, Boris [1 ]
Purcell, Carrie [3 ]
Levey, Andrew S. [4 ,5 ]
Smith, Mari [3 ]
Abdoli, Amir [6 ]
Abebe, Molla [7 ]
Adebayo, Oladimeji M. [11 ]
Afarideh, Mohsen [19 ]
Agarwal, Sanjay Kumar [23 ]
Agudelo-Botero, Marcela [24 ]
Ahmadian, Elham [27 ,30 ]
Al-Aly, Ziyad [31 ,32 ]
Alipour, Vahid [35 ,36 ]
Almasi-Hashiani, Amir [43 ]
Al-Raddadi, Rajaa M. [40 ]
Alvis-Guzman, Nelson [41 ,42 ]
Amini, Saeed [45 ]
Andrei, Tudorel [46 ]
Andrei, Catalina Liliana [49 ]
Andualem, Zewudu [10 ]
Anjomshoa, Mina [50 ]
Arabloo, Jalal [35 ]
Ashagre, Alebachew Fasil [7 ]
Asmelash, Daniel [7 ]
Ataro, Zerihun [51 ]
Atout, Maha Moh'd Wahbi [52 ]
Ayanore, Martin Amogre [53 ]
Badawi, Alaa [54 ,55 ]
Bakhtiari, Ahad [20 ]
Ballew, Shoshana H. [57 ]
Balouchi, Abbas [39 ]
Banach, Maciej [60 ,61 ]
Barquera, Simon [63 ]
Basu, Sanjay [65 ]
Bayih, Mulat Tirfie [68 ]
Bedi, Neeraj [70 ,71 ]
Bello, Aminu K. [72 ]
Bensenor, Isabela M. [73 ]
Bijani, Ali [75 ]
Boloor, Archith [77 ]
Borzi, Antonio M. [78 ]
Camera, Luis Alberto [79 ,80 ]
Carrero, Juan J. [82 ]
Carvalho, Felix [88 ]
Castro, Franz [89 ]
Catala-Lopez, Ferran [90 ,91 ]
Chang, Alex R. [92 ]
Chin, Ken Lee [93 ]
Chung, Sheng-Chia [95 ,96 ]
Cirillo, Massimo [97 ]
机构
[1] IRCCS, Ist Ric Farmacol Mario Negri, Ranica, Italy
[2] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA USA
[3] Univ Washington, Sch Med, Inst Hlth Metr & Evaluat, Seattle, WA USA
[4] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA
[5] Tufts Univ, Sch Med, Boston, MA 02111 USA
[6] Jahrom Univ Med Sci, Dept Parasitol & Mycol, Jahrom, Iran
[7] Univ Gondar, Dept Clin Chem, Gondar, Ethiopia
[8] Univ Gondar, Dept Clin Pharm, Gondar, Ethiopia
[9] Univ Gondar, Dept Epidemiol & Biostat, Gondar, Ethiopia
[10] Univ Gondar, Environm & Occupat Hlth & Safety Dept, Gondar, Ethiopia
[11] Univ Coll Hosp, Dept Med, Ibadan, Nigeria
[12] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden
[13] Univ Tehran Med Sci, Dept Cardiol, Tehran, Iran
[14] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran
[15] Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, Iran
[16] Univ Tehran Med Sci, Dept Microbiol, Tehran, Iran
[17] Univ Tehran Med Sci, Dept Pharmacol, Tehran, Iran
[18] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran
[19] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran
[20] Univ Tehran Med Sci, Hlth Policy Econ & Management, Tehran, Iran
[21] Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, Iran
[22] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[23] All India Inst Med Sci, Dept Nephrol, New Delhi, India
[24] Univ Nacl Autonoma Mexico, Sch Med, Ctr Polit Populat & Hlth Res, Mexico City, DF, Mexico
[25] Tabriz Univ Med Sci, Dept Pharmacol & Toxicol, Tabriz, Iran
[26] Tabriz Univ Med Sci, Med Surg Dept, Tabriz, Iran
[27] Tabriz Univ Med Sci, Pharmacol & Toxicol, Tabriz, Iran
[28] Tabriz Univ Med Sci, Sch Nutr & Food Sci, Tabriz, Iran
[29] Baku State Univ, Dept Physiol, Baku, Azerbaijan
[30] Baku State Univ, Inst Radiat Problems Azerbaijan, Baku, Azerbaijan
[31] Washington Univ, John T Milliken Dept Internal Med, St Louis, MO 63110 USA
[32] US Dept Vet Affairs, VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, St Louis, MO USA
[33] US Dept Vet Affairs, Dept Internal Med, St Louis, MO USA
[34] Iran Univ Med Sci, Colorectal Res Ctr, Tehran, Iran
[35] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran
[36] Iran Univ Med Sci, Hlth Econ Dept, Tehran, Iran
[37] Iran Univ Med Sci, Minimally Invas Surg Res Ctr, Tehran, Iran
[38] Iran Univ Med Sci, Pars Adv & Minimally Invas Med Manners Res Ctr, Tehran, Iran
[39] Iran Univ Med Sci, Sch Nursing & Midwifery, Tehran, Iran
[40] King Abdulaziz Univ, Dept Family & Community Med, Jeddah, Saudi Arabia
[41] Univ Cartagena, Hlth Econ Res Grp, Cartagena, Colombia
[42] Univ Coast, Res Grp Hosp Management & Hlth Policies, Barranquilla, Colombia
[43] Arak Univ Med Sci, Dept Epidemiol, Arak, Iran
[44] Arak Univ Med Sci, Dept Pediat, Arak, Iran
[45] Arak Univ Med Sci, Hlth Serv Management Dept, Arak, Iran
[46] Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, Romania
[47] Carol Davila Univ Med & Pharm, Anat & Embryol, Bucharest, Romania
[48] Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, Romania
[49] Carol Davila Univ Med & Pharm, Bucharest, Romania
[50] Rafsanjan Univ Med Sci, Social Determinants Hlth Res Ctr, Rafsanjan, Iran
关键词
PERIPHERAL ARTERIAL-DISEASE; GLOMERULAR-FILTRATION-RATE; SUB-SAHARAN AFRICA; CKD-EPI EQUATION; CARDIOVASCULAR OUTCOMES; COST-EFFECTIVENESS; RENAL-DISEASE; RISK-FACTOR; ATHEROSCLEROSIS RISK; HEART-FAILURE;
D O I
10.1016/S0140-6736(20)30045-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and induded incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. Findings Globally, in 2017,1.2 million (95% uncertainty interval [UI] 1.2 to 1.3) people died from CKD. The global all-age mortality rate from CKD increased 41.5% (95% UI 35.2 to 46.5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2.8%, -1.5 to 6.3). In 2017,697.5 million (95% UI 649.2 to 752.0) cases of all-stage CKD were recorded, for a global prevalence of 9.1% (8.5 to 9.8). The global all-age prevalence of CKD increased 29.3% (95% UI 26.4 to 32.6) since 1990, whereas the age-standardised prevalence remained stable (1.2%, -1.1 to 3.5). CKD resulted in 35.8 million (95% UI 33.7 to 38.0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1.4 million (95% UI 1.2 to 1.6) cardiovascular disease-related deaths and 25.3 million (22.2 to 28.9) cardiovascular disease DALYs were attributable to impaired kidney function. Interpretation Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:709 / 733
页数:25
相关论文
共 89 条
  • [1] [Anonymous], 2017, Tracking Universal Health Coverage: 2017 Global Monitoring Report
  • [2] [Anonymous], 2016, USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States
  • [3] [Anonymous], CHRON KIDN DIS PROGN
  • [4] [Anonymous], PENNSYLVANIA GEISING
  • [5] Ashuntantang G, 2017, LANCET GLOB HEALTH, V5, pE408, DOI [10.1016/S2214-109X(17)30057-8, 10.1016/s2214-109x(17)30057-8]
  • [6] Chronic kidney disease among adult participants of the ELSA-Brasil cohort: association with race and socioeconomic position
    Barreto, Sandhi M.
    Ladeira, Roberto M.
    Duncan, Bruce B.
    Schmidt, Maria Ines
    Lopes, Antonio A.
    Bensenor, Isabela M.
    Chor, Dora
    Griep, Rosane H.
    Vidigal, Pedro G.
    Ribeiro, Antonio L.
    Lotufo, Paulo A.
    Mill, Jose Geraldo
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2016, 70 (04) : 380 - 389
  • [7] Assessment of Global Kidney Health Care Status
    Bello, Aminu K.
    Levin, Adeera
    Tonelli, Marcello
    Okpechi, Ikechi G.
    Feehally, John
    Harris, David
    Jindal, Kailash
    Salako, Babatunde L.
    Rateb, Ahmed
    Osman, Mohamed A.
    Qarni, Bilal
    Saad, Syed
    Lunney, Meaghan
    Wiebe, Natasha
    Johnson, David W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1864 - 1881
  • [8] A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases
    Bikbov, Boris
    Perico, Norberto
    Remuzzi, Giuseppe
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2018, 18
  • [9] Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study
    Bikbov, Boris
    Perico, Norberto
    Remuzzi, Giuseppe
    [J]. NEPHRON, 2018, 139 (04) : 313 - 318
  • [10] Single Estimated Glomerular Filtration Rate and Albuminuria Measurement Substantially Overestimates Prevalence of Chronic Kidney Disease
    Bottomley, M. J.
    Kalachik, A.
    Mevada, C.
    Brook, M. O.
    James, T.
    Harden, P. N.
    [J]. NEPHRON CLINICAL PRACTICE, 2011, 117 (04): : C348 - C352